Xenon Pharmaceuticals
XENE
134 hedge funds and large institutions have $1.51B invested in Xenon Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 48 increasing their positions, 40 reducing their positions, and 16 closing their positions.
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
20% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 40
3% more funds holding
Funds holding: 130 → 134 (+4)
2.35% more ownership
Funds ownership: 92.44% → 94.79% (+2.3%)
1% more capital invested
Capital invested by funds: $1.49B → $1.51B (+$15.4M)
89% less call options, than puts
Call options by funds: $557K | Put options by funds: $5.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$39.7M |
| 2 |
Holocene Advisors
New York
|
+$27.2M |
| 3 |
Morgan Stanley
New York
|
+$17M |
| 4 |
Goldman Sachs
New York
|
+$16.6M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$50.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.3M |
| 3 |
Renaissance Technologies
New York
|
-$6.89M |
| 4 |
Bank of New York Mellon
New York
|
-$6.36M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.66M |
XENE Hedge Fund Activity: Q1 2022 in Review
134 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2022, worth a combined $1.51B — up 1% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new XENE positions and 16 closed out — a net gain of 4 holders — while 48 added to existing stakes and 40 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $39.7M. The largest seller was BVF Inc, cutting an estimated $50.6M.
- 134 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2022, up from 130 in Q4 2021.
- Funds reported $1.51B of Xenon Pharmaceuticals stock for Q1 2022, up 1% quarter-over-quarter.
- 20 funds opened new Xenon Pharmaceuticals positions in Q1 2022 and 16 closed out, a net change of +4 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $39.7M added.
- The largest Xenon Pharmaceuticals seller in Q1 2022 was BVF Inc, an estimated $50.6M sold.
Based on aggregated 13F filings for Q1 2022.